Biomedical Engineering_Texas A&M Engineering_Flickr Texas AM Engineering/Flickr

Biomedicine in Reverse

Pundits have long predicted that biology would dominate the twenty-first century, just as physics dominated the twentieth century. But, with investment in biomedical R&D falling rapidly in recent years, the “century of biology” may turn out to be little more than a fantasy.

LA JOLLA, CALIFORNIA – Pundits have long predicted that biology would dominate the twenty-first century, just as physics dominated the twentieth century. But biomedical research has yet to achieve the kind of productivity increases that accompanied the industrialization of combustion, electricity, and electronics. Will the “century of biology” turn out to be little more than a fantasy?

The problem largely comes down to a decrease in biomedical research-and-development expenditure. As it stands, roughly $270 billion is invested in the field each year, producing an impressive half-million research publications, but only 20-30 new medicines.

The discrepancy between spending and output adheres to what has come to be known as “Eroom’s law” – Moore’s law in reverse. Moore’s law observes the increase in computer processing power over time – specifically, that the number of transistors that can be placed cheaply on an integrated circuit doubles every 18-24 months. By contrast, Eroom’s law charts the regress in new drug approvals, noting that the costs of developing a new medicine double roughly every nine years.

We hope you're enjoying Project Syndicate.

To continue reading, subscribe now.

Subscribe

Get unlimited access to PS premium content, including in-depth commentaries, book reviews, exclusive interviews, On Point, the Big Picture, the PS Archive, and our annual year-ahead magazine.

http://prosyn.org/JNZpjB1;

Handpicked to read next

  1. verhofstadt40_PAULFAITHAFPGettyImages_borisjohnsonspeakingarms Paul Faith/AFP/Getty Images

    Boris’s Big Lie

    Guy Verhofstadt

    While Boris Johnson, the likely successor to British Prime Minister Theresa May, takes his country down a path of diminished trade, the European Union is negotiating one of the largest free-trade agreements in the world. One really has to wonder what the "buccaneering" Brexiteers have to complain about.

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.